Novozymes, the world leader in biological solutions, announced the acquisition of the microbiome R&D team and data science platform of Biota.

The addition of Biota’s R&D team and data science platform will give Novozymes a technical edge for pursuing new opportunities and further strengthen existing solutions in OneHealth, Novozymes’ human health unit.

“The experience of the R&D team from Biota in translating complex microbiome and genomics data into biological insights and health benefits using their world-class data science platform will be key to advancing our leading probiotics pipeline as well as pursuing new opportunities for future growth.”

Novozymes has acquired this data science platform for an undisclosed amount that is immaterial to Novozymes financials.

Biota will retain a commercial license to apply the data science platform for genomic diagnostics.